Everardus Orlemans is the new vice president for clinical research at Pozen (Nasdaq: POZN).
Orlemans is responsible for clinical trials to support New Drug Application (NDA) submissions by Pozen to the Food and Drug Administration and other worldwide regulatory bodies.
Orlemans worked most recently as executive director of the clinical development unit for Organon Pharmaceuticals USA. He has been involved in more than 10 NDAs in the U.S. and three others elsewhere. A PhD, Orlemans is also co-author of five patents.